
- December 2016 Heart Health
- Volume 82
- Issue 12
Generic Product News (December 2016)
Read about the new generic products featured in December.
LIDOCAINE OINTMENT USP, 5% 
Marketed by: Glenmark Pharmaceuticals, Inc
Compare to: Xylocaine Ointment, 5% (AstraZeneca)
Indication: Glenmark Pharmaceuticals, Inc, has announced final approval for its generic version of Xylocaine Ointment, 5%. Lidocaine Ointment USP, 5%, is indicated for production of anesthesia of accessible mucous membranes of the oropharynx. It is also used as an anesthetic lubricant for intubation and temporary relief of pains associated with minor burns, including sunburn, skin abrasions, and insect bites.
Dosage Forms: Topical
For More Information: glenmarkpharma.com
MEROPENEM FOR INJECTION, USP (I.V.)
Marketed by: Amneal
Compare to: Merrem (AstraZeneca)
Indication: Amneal has launched Meropenem for Injection, USP (I.V.), an AP-rated generic equivalent to Merrem. Meropenem is indicated for the treatment of complicated skin and skin structure infections, intraabdominal infections, and bacterial meningitis.
Dosage Forms: Injection: 500- mg and 1-g per vial strengths in 10-count packages
For More Information: AmnealBiosciences.com
ROSUVASTATIN CALCIUM TABLETS
Marketed by: Camber
Compare to: Crestor (AstraZeneca)
Indication: Camber has announced that it has launched the generic version of Crestor tablets. Rosuvastatin indicated to treat high cholesterol and triglyceride levels.
Dosage Forms: Tablets: 5, 10, and 20 mg in 90-count bottles; 40 mg in 30-count bottles
For More Information: camberpharma.com
DUTASTERIDE CAPSULES
Marketed by: Camber
Compare to: Avodart (GlaxoSmithKline)
Indication: Camber has launched the generic version of Avodart capsules. Dutasteride is indicated for the treatment of an enlarged prostate.
Dosage Forms: Capsules: 0.5 mg in 30- and 90-count bottles
For More Information: camberpharma.com
Articles in this issue
almost 9 years ago
Recent Safety Data: Implications for Use of Proton Pump Inhibitorsalmost 9 years ago
Case Studies (December 2016)almost 9 years ago
Can You Read These Rxs? (December 2016)almost 9 years ago
Pet Peeves (December 2016)almost 9 years ago
US Generics Market Forecasted to Grow from 2016 to 2020almost 9 years ago
Meeting Patients Where They Arealmost 9 years ago
Managing Workplace Changealmost 9 years ago
Comprehensive Addiction and Recovery Act of 2016almost 9 years ago
Termination of Employment Due to a Past Adverse Board ActionNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.




















































































































































































































